3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Endocrine
1
Conditions
Carcinoma, Non-Small-Cell Lung
235
Breast Neoplasms
233
Prostatic Neoplasms
170
Multiple Myeloma
151
Neoplasms
134
Colorectal Neoplasms
126
Leukemia, Myeloid, Acute
121
Lung Neoplasms
108
Neoplasm Metastasis
101
Squamous Cell Carcinoma of Head and Neck
94
Carcinoma, Hepatocellular
88
Melanoma
86
Lymphoma
82
Triple Negative Breast Neoplasms
77
Pancreatic Neoplasms
76
Ovarian Neoplasms
71
Sarcoma
68
Carcinoma, Renal Cell
64
Recurrence
63
Lymphoma, Large B-Cell, Diffuse
63
Brain Neoplasms
63
Precursor Cell Lymphoblastic Leukemia-Lymphoma
60
Head and Neck Neoplasms
57
Lymphoma, Non-Hodgkin
56
Stomach Neoplasms
54
Leukemia, Lymphocytic, Chronic, B-Cell
54
Endometrial Neoplasms
53
Hematologic Neoplasms
52
Urinary Bladder Neoplasms
50
Small Cell Lung Carcinoma
49
Interventions
trametinib
1
dabrafenib
1
Thyrotropin Alfa
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Metastatic Radioactive Iodine Refractory Thyroid Cancer Patients With RAS or BRAF Mutation
×
90 days
×
Clear all
NCT03244956
2026-03-23
MERAIODE
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2
Completed
40 enrolled